In addition, because the CGRP-related adrenomedullin (ADM) peptide, which mainly signals through the CLR/RAMP2 receptor, has been implicated in the development of inflammatory hyperalgesia and migraine pain and because CGRP and ADM receptors are systematically present in human trigeminal ganglia (Moreno et al., 1999), a peptide antagonist that can target multiple CLR/RAMP receptors may have a better potential to alleviate headaches in patients with severe migraine (Ma et al., 2006; Fernandez et al., 2010; Wang et al., 2011; Zeng et al., 2014; Garelja and Hay, 2022; Rees et al., 2022). This evidence concerns the gene ADM and migraine disorder.